Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer

BACKGROUND: The rising cost of cancer drug therapy threatens the long-term sustainability of Taiwan National Health Insurance. Cost savings can be achieved through various strategies, e.g., using smaller vial sizes, sharing vials, weight-based dosing, or switching to biosimilars. Here we aimed to ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, John Hang, Tai, Yun-sheng, Wang, Shyh-Yau, Yip Fion, Hei-Tung, Tsung-chin, Ho, Chan, Agnes LF.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305615/
https://www.ncbi.nlm.nih.gov/pubmed/35870421
http://dx.doi.org/10.1016/j.breast.2022.07.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305615/
https://www.ncbi.nlm.nih.gov/pubmed/35870421
http://dx.doi.org/10.1016/j.breast.2022.07.007

Ejemplares similares